Efficacy and Safety Study of F520 Combined With Lenvatinib in the Treatment of Patients With Advanced Solid Tumors - Trial NCT05740215
Access comprehensive clinical trial information for NCT05740215 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Shandong New Time Pharmaceutical Co., LTD and is currently Recruiting. The study focuses on Solid Tumors. Target enrollment is 158 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Shandong New Time Pharmaceutical Co., LTD
Timeline & Enrollment
Phase 1/2
May 23, 2022
May 22, 2024
Primary Outcome
Serious adverse events,Adverse events,Dose-limiting toxicity (DLT),Maximum tolerated dose (MTD),Phase II recommended dose (RP2D).,Objective Response Rate (ORR)
Summary
This is a multicenter, open-label, phase Ib/II study on the efficacy and safety of F520
 combined with lenvatinib in the treatment of patients with advanced solid tumors. About
 138~158 patients with advanced solid tumors plan to be enrolled in about 30 study sites of
 the study.
 
 Part I: Phase Ib study evaluating the safety and tolerability of F520 combined with
 lenvatinib in patients with advanced solid tumors.
 
 Part II: Phase II study of F520 combined with lenvatinib in endometrial cancer and cervical
 cancer.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05740215
Non-Device Trial